Quisovalimab

Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF) -related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies[1].

Product Specifications

CAS Number

[2427667-03-4]

Product Name Alternative

AVTX-002; AEVI 002; SAR 252067; CERC-002; MDGN-002

UNSPSC

12352203

Target

SARS-CoV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/quisovalimab.html

Purity

97.78

Solubility

10 mM in DMSO

Smiles

[Quisovalimab]

Molecular Weight

(144.32 kDa)

References & Citations

[1]David S Perlin, et al. Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS. mSphere. 2020 Aug 12;5 (4) :e00699-20.